Combination therapy in epilepsy: When and what to use

Drugs

Volumn 66, Issue 14, 2006, Pages 1817-1829

  Kwan, Patrick ^a   Brodie, Martin J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; INDAPAMIDE; LAMOTRIGINE; OXCARBAZEPINE; PERINDOPRIL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; EPILEPSY; FETUS MALFORMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METABOLISM; NEUROTOXICITY; PREGNANCY; PRESCRIPTION; REVIEW; RISK FACTOR; SEIZURE; TREATMENT FAILURE; TUBERCULOSIS;

ANTICONVULSANTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; SEIZURES; TREATMENT FAILURE;

EID: 33750045736     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666140-00004     Document Type: Review

References (69)

1. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: 1-10
2. Reynolds EH, Chadwick D, Galbraith AW. One drug (phenytoin) in the treatment of epilepsy. Lancet 1976; 307: 923-6
3. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. BMJ 1979; 2: 1023-5
4. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368-76
5. Albright P, Bruni J. Reduction of polypharmacy in epileptic patients. Arch Neurol 1985; 42: 797-9
6. Deckers C. Overtreatment in adults with epilepsy. Epilepsy Res 2002; 52: 43-52
7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9
8. Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localisation-related epilepsies. Seizure 2005; 14: 318-23
9. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006; 13: 277-82
10. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60 Suppl. 4: 2-12
11. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001; 90: 21-34
12. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-64
13. Mawer CE, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995; 68: 209-31
14. Deckers CLP, Hekster YA, Keyser A, et al. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997; 38: 570-5
15. Deckers CLP, Hekster YA, Keyser A, et al. Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 1997; 62: 592-5
16. WHO Collaborating Centre for Drug Statistics Methodology. ATC / DDD Index 2006 [online]. Available from URL: http://www.whocc.no/atcddd [Accessed 2005 Dec 28]
17. Lammers MW, Hekster YA, Keyser A, et al. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36: 440-6
18. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-91
19. Cunnington M, Tennis P, for the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955-60
20. Morrow JI, Russell A, Gutherie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8
21. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-56
22. Radulov LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 1995; 35: 155-61
23. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407-13
24. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707-24
25. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023-42
26. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763-80
27. PROGRESS Collaborative Group. Randomised trial of perinopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41
28. Czuczwar SJ, Borowicz KK. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002; 52: 15-23
29. Temkin MR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: metanalysis of controlled trials. Epilepsia 2001; 42: 515-24
30. Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004; 9: 110-9
31. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005; 19: 897-908
32. Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387-94
33. Baldy-Moulinier M, Covanis A, et al. Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. Seizure 1998; 7: 513-20
34. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005; 7 Suppl. 1: S1-64
35. Deckers CLP. Place of polytherapy in the early treatment of epilepsy. CNS Drugs 2002; 16: 155-63
36. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9: 464-8
37. Beghi E, Gatti G, Tonini C, et al. Adjuctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57: 1-13
38. Lindberger M, Alenius M, Frisen L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. Epilepsia 2000; 41: 1289-95
39. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80
40. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001; 46: 259-70
41. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600
42. Brodie MJ, Yuen AWC. Lamotrigine substitution study: synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423-32
43. Pisani F, Otero G, Russo MF, et al. The efficacy of valproate-lamotrigine comedicatoin in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6
44. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797-802
45. Cereghino JJ, Brock JT, Van-Meter JC, et al. The efficacy of carbamazepine combination in epilepsy. Clin Pharmacol Ther 1975; 18: 733-41
46. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study Group. Epilepsy Res 1999; 34: 199-205
47. Leach JP, Brodie MJ. Synergism with GABA-ergic drugs in refractory epilepsy. Lancet 1994; 343: 1650
48. Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351: 958-9
49. Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364-74
50. Kwan P, Brodie MJ. Pharmacological treatment of epilepsy in adolescents and adults. In: Gilman S, editor. MedLink Neurology [online]. Available from URL: http://medlink.com [Accessed 2006 Sep 5]
51. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002; 11: 349-51
52. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-7
53. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-607
54. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60
55. Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005; 6: 382-7
56. Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001; 18: 1-12
57. Trevathan E, Gilliam F. Lost years: delayed referral for surgically treatable epilepsy. Neurology 2003; 61: 432-3
58. Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998; 10: 171-9
59. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-56
60. Pellock JM, Brodie MJ. Felbamate: an update. Epilepsia 1997; 38: 1261-4
61. McDonagh J. Stephen LJ, Dolan F, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 1690-4
62. Arts WFM, Geerts AT, Brouwer OF, et al. The early prognosis of epilepsy in childhood: the prediction of a poor outcome. Epilepsia 1999; 40: 726-34
63. MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48: 833-41
64. Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56: 1445-52
65. Brodie MJ. Glasgow outcome studies. Epilepsy Res 2004; 60: 96-7
66. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005; 46: 225-35
67. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602
68. Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006; 6: 397-406
69. Brandt C, Bethmann K, Gastens A, et al. Resistance to antiepileptic drug treatment can be counteracted by inhibition of P-glycoprotein in a rat model of temporal lobe epilepsy [abstract]. Epilepsia 2005; 46 Suppl. 6: 60